EUCTR2013-003303-18-PL
Active, not recruiting
Phase 1
Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnosed or undiagnosed allergic disease
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Recurrent airway inflammation in children with impaired cellular immunity.
- Sponsor
- Gedeon Richter Polska Sp. z o. o.
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1 Age\> 24 months to \<12 years at inclusion in the study.
- •2 Consent of parent / legal representative of the child to participate in the study, confirmed by signing the Informed Consent Form for Parent / legal representative of the patient before the first study procedures and after obtaining explanations concerning the design and purpose of the study;
- •3 Frequent respiratory infection (not less than 6 cases per year), of chronic (\> 10 days), difficult to treat (the slow process of recovery).
- •4 Patients with laboratory\-confirmed impaired cellular immunity (reduction in absolute number and / or interest of T cells and / or impairment of the function) with a possible simultaneous slight decrease in the level of fractions of IgG, IgM, IgA.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 60
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1 Renal failure , determined on the basis of clinical evaluation and laboratory tests .
- •2 Gout , kidney stones and increased uric acid in the blood indicated on the basis of medical history and laboratory tests .
- •3 Hypersensitivity to the active substance or any Groprinosin drug excipients .
- •4 Patients with rare hereditary problems of fructose intolerance, glucose\-galactose malabsorption or sucrase \- isomaltase insufficiency.
- •5 Administration of xanthine oxidase inhibitors , diuretics or azidothymidine .
- •6 Currently recognized infectious or contagious disease or inflammation of different etiologies and the need for antibiotic treatment.
- •7 The use of immunostimulatory drugs (including nonspecific vaccines ) or immunosuppressants within 6 months or corticosteroids\- systemic, inhaled and used externally within 1 month prior to inclusion in the study.
- •8 The use of specific immunotherapy and vaccinations within 4 weeks prior to enrollment .
- •9 The use of antibiotic therapy within 1 month prior to inclusion in the study.
- •10 Another reason , which in the opinion of the investigator disqualify a patient from the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Trial to evaluate efficacy and safety of modified new drug of Pranlukast(Prakanon), compared with Pranlukast (Onon®)Diseases of th respiratory systemKCT0000457Ewha Womans University Medical Center40
Active, not recruiting
Phase 1
utility study of a predictive system for ambulatory colonoscopy preparatioEUCTR2017-000787-15-ESAntonio Zebenzui Gimeno García300
Not yet recruiting
Phase 4
Phase IV clinical study on the safety and effectiveness of Sanqi Longxuejie Capsules in the treatment of coronary heart disease with stable exertional angina pectoris (Grade I, II)ITMCTR2100005341Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences
Recruiting
Phase 4
Phase IV Efficacy Study of MMR Vaccine in Preventing or Reduction of Severity of COVID-19 in Healthcare Workers AdultsRBR-2xd6dkjniversidade Federal de Santa Catarina
Active, not recruiting
Phase 1
Study comparing the efficacy and safety of Benzydamine hydrochloride 0,3% oromucosal spray and Benzydamine hydrochloride 3 mg lozenges in patients with acute sore throat.acute sore throatTherapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]EUCTR2019-003257-29-HUAngelini S.p.A.363